Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion
Background: Polymyxin B direct hemoperfusion (PMX-DHP) has been tried in acute exacerbation of interstitial lung disease (AE-ILD) patients and has shown clinical benefit. In this study, we tried to investigate the change in oxygenation and serologic markers after PMX-DHP treatment in AE-ILD patients...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/9/2485 |
| _version_ | 1797504184155635712 |
|---|---|
| author | Song-I Lee Chaeuk Chung Dongil Park Da Hyun Kang Jeong Eun Lee |
| author_facet | Song-I Lee Chaeuk Chung Dongil Park Da Hyun Kang Jeong Eun Lee |
| author_sort | Song-I Lee |
| collection | DOAJ |
| description | Background: Polymyxin B direct hemoperfusion (PMX-DHP) has been tried in acute exacerbation of interstitial lung disease (AE-ILD) patients and has shown clinical benefit. In this study, we tried to investigate the change in oxygenation and serologic markers after PMX-DHP treatment in AE-ILD patients in Korea. Methods: We reviewed the medical records of twenty-two patients who were admitted for AE-ILD and underwent PMX-DHP treatment. Changes in vital signs and laboratory findings before and after treatment were compared and factors related to 90-day mortality were analyzed using the Cox regression model. Results: Of the 22 included patients, 11 (50%) patients were diagnosed with idiopathic pulmonary fibrosis. In AE-ILD patients treated with PMX-DHP, the 28-day mortality rate was 45.5% and the 90-day mortality rate was 72.7%. The P/F ratio before and after PMX-DHP treatment significantly improved in patients from baseline to 24 h (median (IQR), 116.3 (88.5–134.3) mmHg vs. 168.6 (115.5–226.8) mmHg, <i>p</i> = 0.001), and 48 h (116.3 (88.5–134.3) mmHg vs. 181.6 (108.9–232.0) mmHg, <i>p</i> = 0.003). Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. High acute physiology and chronic health evaluation II scores were associated with 90-day mortality. Conclusions: In patients with AE-ILD, PMX-DHP treatment was associated with an improved P/F ratio and lower WBC and CRP levels. |
| first_indexed | 2024-03-10T04:01:03Z |
| format | Article |
| id | doaj.art-07fca922a142495583ab5cf487ec7cc1 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:01:03Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-07fca922a142495583ab5cf487ec7cc12023-11-23T08:33:01ZengMDPI AGJournal of Clinical Medicine2077-03832022-04-01119248510.3390/jcm11092485Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B HemoperfusionSong-I Lee0Chaeuk Chung1Dongil Park2Da Hyun Kang3Jeong Eun Lee4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Munhwa-ro, Jung-gu, Daejeon 35015, KoreaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Munhwa-ro, Jung-gu, Daejeon 35015, KoreaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Munhwa-ro, Jung-gu, Daejeon 35015, KoreaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Munhwa-ro, Jung-gu, Daejeon 35015, KoreaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Munhwa-ro, Jung-gu, Daejeon 35015, KoreaBackground: Polymyxin B direct hemoperfusion (PMX-DHP) has been tried in acute exacerbation of interstitial lung disease (AE-ILD) patients and has shown clinical benefit. In this study, we tried to investigate the change in oxygenation and serologic markers after PMX-DHP treatment in AE-ILD patients in Korea. Methods: We reviewed the medical records of twenty-two patients who were admitted for AE-ILD and underwent PMX-DHP treatment. Changes in vital signs and laboratory findings before and after treatment were compared and factors related to 90-day mortality were analyzed using the Cox regression model. Results: Of the 22 included patients, 11 (50%) patients were diagnosed with idiopathic pulmonary fibrosis. In AE-ILD patients treated with PMX-DHP, the 28-day mortality rate was 45.5% and the 90-day mortality rate was 72.7%. The P/F ratio before and after PMX-DHP treatment significantly improved in patients from baseline to 24 h (median (IQR), 116.3 (88.5–134.3) mmHg vs. 168.6 (115.5–226.8) mmHg, <i>p</i> = 0.001), and 48 h (116.3 (88.5–134.3) mmHg vs. 181.6 (108.9–232.0) mmHg, <i>p</i> = 0.003). Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment. High acute physiology and chronic health evaluation II scores were associated with 90-day mortality. Conclusions: In patients with AE-ILD, PMX-DHP treatment was associated with an improved P/F ratio and lower WBC and CRP levels.https://www.mdpi.com/2077-0383/11/9/2485interstitial lung diseaseidiopathic pulmonary fibrosispolymyxin Bbiochemical markerprognosis |
| spellingShingle | Song-I Lee Chaeuk Chung Dongil Park Da Hyun Kang Jeong Eun Lee Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion Journal of Clinical Medicine interstitial lung disease idiopathic pulmonary fibrosis polymyxin B biochemical marker prognosis |
| title | Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion |
| title_full | Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion |
| title_fullStr | Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion |
| title_full_unstemmed | Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion |
| title_short | Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion |
| title_sort | changes in oxygenation and serological markers in acute exacerbation of interstitial lung disease treated with polymyxin b hemoperfusion |
| topic | interstitial lung disease idiopathic pulmonary fibrosis polymyxin B biochemical marker prognosis |
| url | https://www.mdpi.com/2077-0383/11/9/2485 |
| work_keys_str_mv | AT songilee changesinoxygenationandserologicalmarkersinacuteexacerbationofinterstitiallungdiseasetreatedwithpolymyxinbhemoperfusion AT chaeukchung changesinoxygenationandserologicalmarkersinacuteexacerbationofinterstitiallungdiseasetreatedwithpolymyxinbhemoperfusion AT dongilpark changesinoxygenationandserologicalmarkersinacuteexacerbationofinterstitiallungdiseasetreatedwithpolymyxinbhemoperfusion AT dahyunkang changesinoxygenationandserologicalmarkersinacuteexacerbationofinterstitiallungdiseasetreatedwithpolymyxinbhemoperfusion AT jeongeunlee changesinoxygenationandserologicalmarkersinacuteexacerbationofinterstitiallungdiseasetreatedwithpolymyxinbhemoperfusion |